Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Pemazyre
Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. It is an oral, small molecule inhibitor of FGFR1, FGFR2, and FGFR3. Cholangiocarcinoma is a rare and aggressive cancer of the bile ducts. The FGFR2 genetic alteration is a key driver in a subset of cholangiocarcinoma cases.
Pemigatinib is used to treat adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement.
Outcome:
Increased pemigatinib exposure
Mechanism:
Inhibition of CYP2C8-mediated metabolism
Outcome:
Increased pemigatinib exposure
Mechanism:
Partial inhibition of CYP2C8 metabolism
Outcome:
Minimal increase in pemigatinib exposure
Mechanism:
Weak inhibition of CYP2C8 metabolism
Most likely new formulation: Combination therapy with other targeted agents or chemotherapy (Year: 2025, 70% confidence)
Based on clinical trial data and current usage trends, there is a high likelihood (>80%) that pemigatinib will remain a standard treatment option for FGFR2-fusion positive cholangiocarcinoma.
Kinase Inhibitor, Antineoplastic Agent
Indazole derivative